Novel strategies for the treatment of sepsis.

Nature medicine ·Vol. 9 ·No. 5 ·2003-05-00 ·Pages 517-24

Riedemann NC, Guo RF, Ward PA

Abstract

The history of therapeutic interventions in clinical trials for sepsis has been referred to as the "graveyard for pharmaceutical companies." That is now set to change, as research provides hope for new approaches that will be therapeutically effective in humans with sepsis.

MeSH Terms

Animals Antigens, CD Apoptosis Complement C5a/antagonists & inhibitors HMGB1 Protein/physiology Humans Macrophage Migration-Inhibitory Factors/physiology Protein C/therapeutic use Receptor, Anaphylatoxin C5a Receptors, Complement/antagonists & inhibitors Sepsis/drug therapy,etiology

Chemicals

Antigens, CD HMGB1 Protein Macrophage Migration-Inhibitory Factors Protein C Receptor, Anaphylatoxin C5a Receptors, Complement Complement C5a

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Riedemann Niels C

Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Guo Ren-Feng

Ward Peter A

Article Info

Journal

Nature medicine

Abbr.

Nat Med

ISSN

1078-8956

DOI

10.1038/nm0503-517

Published

2003-05-00

Pages

517-24

Language

English

Region

United States

NLM ID

9502015

Subset

External Links

PubMed source DOI: 10.1038/nm0503-517 View journal details

Analysis Services

Novel strategies for the treatment of sepsis.

Contact

WeChat Official Account